Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
2 competitors in Advanced Renal Cell Carcinoma
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Fotivda
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.
View on EMAPreviously Untreated Relapsed Refractory Acute Myeloid Leukemia
Carcinoma, Renal Cell
Renal Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
